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Aluminum oxyhydroxide (alum) is a crystalline compound widely used as an immunolog-
ical adjuvant of vaccines. Concerns linked to the use of alum particles emerged follow-
ing recognition of their causative role in the so-called macrophagic myofasciitis (MMF)
lesion detected in patients with myalgic encephalomyelitis/chronic fatigue/syndrome. MMF
revealed an unexpectedly long-lasting biopersistence of alum within immune cells in pre-
sumably susceptible individuals, stressing the previous fundamental misconception of its
biodisposition.We previously showed that poorly biodegradable aluminum-coated particles
injected into muscle are promptly phagocytosed in muscle and the draining lymph nodes,
and can disseminate within phagocytic cells throughout the body and slowly accumulate in
brain.This strongly suggests that long-term adjuvant biopersistence within phagocytic cells
is a prerequisite for slow brain translocation and delayed neurotoxicity. The understanding
of basic mechanisms of particle biopersistence and brain translocation represents a major
health challenge, since it could help to define susceptibility factors to develop chronic
neurotoxic damage. Biopersistence of alum may be linked to its lysosome-destabilizing
effect, which is likely due to direct crystal-induced rupture of phagolysosomal membranes.
Macrophages that continuously perceive foreign particles in their cytosol will likely reit-
erate, with variable interindividual efficiency, a dedicated form of autophagy (xenophagy)
until they dispose of alien materials. Successful compartmentalization of particles within
double membrane autophagosomes and subsequent fusion with repaired and re-acidified
lysosomes will expose alum to lysosomal acidic pH, the sole factor that can solubilize alum
particles. Brain translocation of alum particles is linked to a Trojan horse mechanism previ-
ously described for infectious particles (HIV, HCV), that obeys to CCL2, signaling the major
inflammatory monocyte chemoattractant.
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Billions of humans have been vaccinated and marked regression
or eradication of several severe infectious diseases was observed.
Nowadays, the potential applications of vaccines extend far beyond
prevention of infectious diseases, and vaccination is considered
to be a most promising weapon against a variety of different
conditions. Vaccine safety has been regarded as excellent at the
level of the population (1), but adverse effects have also been
reported (2).
Concerns about the use of aluminum adjuvants have emerged
following (i) recognition of their role at the origin of the so-called
macrophagic myofasciitis (MMF) lesion in 2001 (3, 4), which
revealed fundamental misconception of their adjuvant effect and
pointed out their unexpectedly long-lasting biopersistence (4);
and (ii) demonstration of their apparent capacity to migrate
in lymphoid organs and then disseminate throughout the body
within monocyte-lineage cells and progressively accumulate in the
brain (5).
The present paper will review these emerging characteristics of
alum adjuvant particles that raise concerns about innocuity of this
widely used compound.
ALUM ADJUVANTS ARE LYSOSOME-DESTABILIZING
PARTICULATE COMPOUNDS
Adjuvants have been used in vaccines for their ability to enhance
the adaptive immune response to a co-administered antigen. Par-
ticulate aluminum salts (known as alum) have been the main
approved adjuvants for use in human vaccines for more than
80 years (6). They are currently used in vaccines against tetanus,
hepatitis A, hepatitis B, human papillomavirus, haemophilus
influenzae B, pneumococcal and meningococcal infections, and
anthrax. They mainly include aluminum oxyhydroxide, a crys-
talline compound, aluminum hydroxyphosphate, and amorphous
aluminum phosphate. Alum is able to adsorb vaccine antigens on
its surface. The strongest adsorption phenomenon results from lig-
and exchange,which involves the replacement of a surface hydroxyl
on the adjuvant by a terminal phosphate group of the antigen (7).
Alum induces strong innate immune responses at the site
of injection, as assessed by an influx of neutrophils, mono-
cyte/macrophages, eosinophils, and MHC-II+ antigen present-
ing cells, mainly dendritic cells (DCs) (8). Muscle-resident
macrophages mainly located in fascias are among the first cells
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to sense disturbance in muscle homeostasis (9). They alert the
immune system through local production of chemokines, and
recruit other myeloid cells, like neutrophils, and inflammatory
monocytes that differentiate into inflammatory DCs (9). Spe-
cialized for antigen uptake, monocyte-derived inflammatory DCs
have an immature phenotype in the muscle. However, they migrate
to the lymph node T-cell paracortex upon contact with tissue
debris or foreign material, and arrive there as mature cells express-
ing costimulatory molecules (10). Inflammatory DCs may be
crucial for the alum adjuvant activity as assessed by selective deple-
tion studies (11), but eosinophils also appear to play an important
role (12).
Alum has been long believed to ensure a long-lasting immune
response through formation of a depot slowly releasing the antigen
under the influence of the interstitial fluid (13, 14). The view that
the injected adjuvant remains extra-cellular has been challenged
by muscle biopsy findings in immunized patients (4). In contrast
to ancient belief, alum particles are avidly taken up by phagocytic
cells (15). The strong binding of antigen to alum particles increases
antigen uptake by DCs, reduces antigen degradation, and sustains
antigen presentation in vitro (16). Macrophage survival may also
be promoted by alum particle uptake (17). Alum injection induces
in vivo the formation of persistent alum-induced granuloma at site
of previous immunization (4, 18, 19). However, good immuniza-
tion does not require local alum persistence, since no decrease of
antigen-specific T- and B-cell responses were observed in case of
removal of the injection site as early as 2 h after injection (20).
In spite of their long usage, the literature has pointed out that
the adjuvanticity mechanisms of aluminum salts remain basically
unknown despite most active investigation in the field in recent
years (21, 22). Alum is deficient at initiating cell-mediated immu-
nity and skews the immune response toward a T-helper type 2
(Th2) response associated with strong production of IL-4 and
the IgG1 antibody subtype (23). Concerning the mechanisms
of alum adjuvanticity, several explanations have been proposed,
most of them being subsequently challenged (24). Notably, the
NLRP3 inflammasome was shown to be strongly activated by
alum (25, 26), but this finally appeared unessential to the adjuvant
effect (27, 28). It remains true, however, that aluminum hydrox-
ide and other crystals such as silica, urate sodium, and asbestos,
strongly induce NLRP3 activation, IL1b release, and activation
of the downstream inflammatory cascade. More recently, alter-
nate models for alum-mediated immunity have been proposed
on the basis of the link of alum adjuvant effects and the release
of non-cytokine biomolecules, including uric acid (29), double-
stranded DNA (30), and prostaglandin E2 (31). The specificity of
crystal-induced signaling pathways has been proposed to explain
why aluminum hydroxide particles exhibit a much more irritat-
ing effect than soluble aluminum (32). Consistently, alum crystals
bind to and aggress the plasma membrane lipid bilayer (33),
destabilizes lysosomes that degrade endocytosed, phagocytosed,
or autophagocytosed materials (34, 35), and play important role
in immunity. Highly controlled antigen processing functions of
DCs use lysosomal proteases and pH changes optimal for the gen-
eration of peptides, rather than complete protein degradation (36).
It is known that limitation of lysosomal proteolysis of antigenic
proteins increases antigen presentation and immunogenicity (37),
and that the stability of peptide:MHCII complexes allowing their
accumulation on the DC surface is enhanced by lysosome activ-
ity inhibition (38). Alum adjuvant mechanisms may thus involve
alum-induced blockade of lysosomes. Alum lysosomal destabi-
lization remains still uncertain, but the physical rupture of the
membrane may be directly caused by the crystalline structure of
alum itself (39).
MMF IS A BIOMARKER ASSESSING LONG-TERM ALUM
BIOPERSISTENCE IN A GIVEN INDIVIDUAL
In 1998, several French myopathologists described MMF as an
emerging condition of unknown cause characterized by a pathog-
nomonic lesion in muscle biopsy mixing large macrophages with
submicron to micron-sized agglomerates of nanocrystals in their
cytoplasm and lymphocytic infiltrates (3), distinct from other his-
tiocytic diseases and always detected in the deltoid muscle of adults
(40). Cytoplasmic inclusions were constantly found, surrounded
or not by altered lysosomal membranes, and contained aluminum
(4). Their crystalline structure was characteristic of aluminum
hydroxide, and no exposure to aluminum other than that con-
ferred by a prior immunization (100%) could be detected (4). It
is now clear that the rapid emergence of MMF in France reflected
the combination of (i) the replacement of the subcutaneous (s.c.)
by the intramuscular (i.m.) route for vaccine injections in the
early 1990s; (ii) the large-scale campaign of primo-vaccination
of French adults against hepatitis B in the mid 1990s; and (iii)
the preferential choice of the deltoid muscle for routine mus-
cle biopsy in France, contrasting with the preferential use of the
biceps brachialis and quadriceps muscles in other countries. Alum-
containing vaccines may also induce skin pseudo-lymphoma in
humans (41), and fibrosarcoma in cats (42).
Macrophagic myofasciitis has been reproduced experimentally
by i.m. vaccination in mice, rats, and monkeys (4, 18, 19). The
experimental lesion invariably shrinks over time (19),and, in mon-
keys, it begins to disappear completely from the muscle between
6 and 12 months after a DTP injection corresponding to 14- to
21-fold the human DTP-equivalent dose of alum (18).
Because of the unethical character of muscle biopsy in asymp-
tomatic individuals, whether or not longstanding MMF may be
commonly present in a hidden form in healthy individuals could
not be directly determined. This seems very unlikely, however,
as shown in a recent review of 130 consecutive deltoid muscle
biopsies performed for diagnostic purposes in myalgic patients
previously immunized with alum-containing vaccines. This study
revealed that most alum receivers do not have long-lasting MMF.
This could be reliably assessed whereas age, sex ratio, number
of alum-adjuvanted injections, and delays elapsed from the last
injection to deltoid muscle biopsy were similar in the MMF and
non-MMF groups (43). This refutes non-documented belief that
every vaccinee may have long-standing MMF lesions when biopsy
is performed in the deltoid muscle (44). In addition, MMF and
non-MMF patients had clinical differences as developed below.
In light of experimental models, it is important to check the
individual vaccine record in each patient to assess the “unusu-
ally persistent” character of MMF. In a recent evaluation of
583 patients collected from 1994 to 2012 (45), the median time
elapsed between the last alum administration and the biopsy was
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65 months. Compared to our previous reports, this time had grad-
ually increased from 36 months in 2001, i.e., shortly after the peak
of French adult immunization, to 53 months in 2003 (46). An aver-
age number of 5.3 alum-containing shots had been administered
during the 10 years prior to biopsy detecting MMF, mainly cor-
responding to vaccinations against hepatitis B (89.7%), tetanus
(42.2%), and hepatitis A (8.8%). In practice, we consider that
the MMF is unusually persistent when time elapsed from last
immunization to the MMF detection exceeds 18 months. It is
important to consider this point in young children who receive
multiple vaccine injections in the first year of life, thus increasing
the risk of coincidental association between a constitutive muscle
disease and MMF detected in the quadriceps muscle used for pedi-
atric immunizations. If the risk of such coincidental associations
also potentially exists in adults, it is low in practice. For exam-
ple, adult patients combining MMF and hereditary muscle disease
is extremely rare, despite the intense immunization program of
patients with muscular dystrophy.
Animal studies indicate that alum-induced granulomatous
lesions considerably vary in size according to the genetic back-
ground (19), and the initial hypothesis made by WHO that MMF
may reflect some individual inability to clear out alum from the
body remains valid (47). In summary, the long-lasting MMF lesion
should be considered as a biomarker assessing unusually long-term
biopersistence of alum in affected individuals.
PATIENTS WITH MMF AT BIOPSY SUFFER MYALGIC
ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME
Macrophagic myofasciitis is typically detected in patients with dif-
fuse myalgias and chronic fatigue, as shown in both the French
series (46) and the recently published series of 16 patients (48).
In both series, most patients are women (70–80%) with a mean
age of 45 years at the time of the biopsy, that typically complain
of myalgias, with or without arthralgia, and disabling chronic
fatigue. The onset of these symptoms is typically delayed from
the immunization.
Strong statistical association between myalgias and MMF was
detected by general survey in different French neuromuscular cen-
ters (myalgias in 90% of patients with MMF vs. 44% without MMF,
p< 0.0001) (4). Onset of myalgia may follow exercise. They usually
begin in the lower limbs, and not at the site of previous immu-
nization from 0.5 to 84 months in the French patients and 3 to
192 months in Portuguese patients. They gradually extend toward
the top of the body, affect the paravertebral muscles, and become
diffuse (46). Myopathic electromyogram and elevation of creatine
kinase (CK) are, respectively, observed in less than half of patients.
Comparison of myalgic vaccinees with and without MMF at del-
toid muscle biopsy showed significant differences: patients with
MMF rarely had fibromyalgia (the required 11 tender points of
the ACR 1990 criteria for fibromyalgia present in 16.6 vs. 55.5%,
p< 0.04), and more often had delayed evoked potentials sugges-
tive of CNS demyelination (38.5 vs. 5.7%, p< 0.01) (43), which
does not support coincidental association.
Chronic fatigue is another important symptom (48, 49).
A case–control study conducted under the aegis of the
French regulatory agency AFSSAPS yielded chronic fatigue as
both significantly more frequent and more severe in patients
with MMF compared to those without MMF in the del-
toid muscle (http://ansm.sante.fr/var/ansm_site/storage/original/
application/030593fa4e393af7cec8ff7092832215.pdf ).
Cognitive alterations further assess CNS involvement that are
disabling though often not detected by routine examination.
Patients complain of memory loss, foggy brain, and mood changes.
Cognitive tests almost constantly show alterations suggestive of
organic cortico-subcortical impairment, impacting visual mem-
ory, working memory, and dichotic listening (50). These deficits
usually remain stable with time (51).
Taken together, chronic muscle pain, chronic fatigue, and
cognitive dysfunction are consistent with the so-called myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) and about
50% of MMF patients meet international criteria for ME/CFS (48,
49). ME/CFS is a severe, complex, acquired illness classified as
a neurological disorder in the WHO International Classification
of Diseases since 1969 (ICD 10 G93.3), distinct from fibromyalgia
and psychasthenia, which are classified as musculoskeletal (M79.7)
and psychiatric (F48.8) disorders, respectively. International stud-
ies have estimated the prevalence of ME/CFS between 0.4 and 2.6%
of the population, with a total annual cost burden to society of
approximately $18.7–$24.0 billion in the USA (52). Symptoms of
ME/CSF are closely similar to the post-infective chronic fatigue
syndrome (53). The underlying cause of ME/CSF is currently
unknown, but the illness is thought to be triggered by an abnor-
mal immune response to an infectious or toxic agent, that results in
chronic immune activation (54). Notably, ME/CFS patients have
increased risk of developing diffuse large B-cell lymphoma and
marginal zone B-cell lymphoma (55). Such a public health bur-
den deserves continued efforts to investigate possible causes and
to understand the pathological mechanisms of CFS.
PHAGOCYTES TRANSPORT ALUM PARTICLES TO THE
LYMPHOID ORGANS AND THEN TO THE BRAIN
The conceptual link between long-term persistence of alum par-
ticles within macrophages at the site of previous immunization,
and the occurrence of adverse systemic events, in particular neuro-
logical ones, has long remained an unsolved question. Aluminum
has long been identified as a neurotoxic metal, affecting memory,
cognition and psychomotor control, altering neurotransmission
and synaptic activity, damaging the blood–brain barrier (BBB),
exerting pro-oxidant effects, activating microglia and neuroin-
flammation,depressing the cerebral glucose metabolism and mito-
chondrial functions, interfering with transcriptional activity, and
promoting beta-amyloid and neurofilament aggregation (56). In
addition, alum particles impact the immune system through their
adjuvant effect and by many other means. They adsorb vaccine
antigens on their surface, which protect them from proteolysis
thus forming a persistently immunogenic pseudo-pathogen (57).
Alum particles may also bind undesirable residual products inher-
ent to vaccine production procedures, as shown for HPV DNA
sequences (58) or yeast proteins (59) that may be potentially haz-
ardous (60). Finally, alum particles can directly induce allergy (61,
62) as other metals (63).
Concerns about long-term biopersistence of alum largely
depend on the ability of alum particles to reach and exert toxi-
city in remote organs. This ability has been suggested by several
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studies (64–67). The reference study on aluminum hydroxide
biodisposition used isotopic 26Al-enriched alum injected in the
rabbit muscle: 26Al was weakly eliminated in the urine (6% on
day 28) and was detected in lymph nodes, spleen, liver, and
brain (13). Whether 26Al was still in particulate form or in sol-
uble form was not explored. The fate of particulate material was
explored in mice by our team. We successively performed i.m.
injections of alum-containing vaccine, fluorescent latex beads,
and fluorescent nanohybrids coated with precipitated alum (5).
These materials were quickly captured by macrophages, a large
proportion of which cleaved the injected muscle, mainly within
immune cells, reaching the draining lymph nodes. Particle-laden
cells then escaped the lymphatic system to reach the blood circu-
lation, presumably via the thoracic duct. In so-doing, they were
able to reach distant organs such as the spleen and liver and, much
slowly, the brain. Recombinant chemokine injection and the use
of genetically modified mice showed that systemic biodistribution
of particles crucially depends on the monocyte chemoattrac-
tant MCP-1/CCL2. Into the brain, particles were mainly found
in microglial cells. In accordance with good overall tolerance of
alum, brain penetration was extremely low in normal conditions.
However, brain translocation was significantly increased in case of
altered BBB or after systemic and/or cerebral increase of the MCP-
1/CCL2 signaling (5). Expression of this chemokine is subjected
to significant interindividual variations related to age, genetic, and
environmental factors. We have identified selective increase of cir-
culating MCP-1/CCL2 in CFS/ME patients with MMF (45). The
imbalance between the huge number of vaccinated individuals and
the relatively low number of MMF cases suggests crucial involve-
ment of individual susceptibility factors in intolerance to alum.
Genetically driven MCP-1/CCL2 production might represent one
of these factors (5).
Thus alum and other poorly biodegradable materials taken up
at the periphery by phagocytes circulate in the lymphatic and blood
circulation and can enter the brain using a Trojan horse mecha-
nism similar to that used by infectious particles (68, 69). Previous
experiments have shown that alum administration can cause CNS
dysfunction and damage (70–72), casting doubts on the exact level
of alum safety (73).
THE CONCEPT OF ASIA
Many CNS diseases likely result from gene–environment inter-
actions. Some of them, such as idiopathic ME/SFC (74) and
multiple sclerosis (MS) (75), have been previously associated with
aluminum overload. An increased risk of developing MS in the
long-term after alum-containing vaccine administration has been
also reported (76, 77), and remains the subject of fierce debate.
Notably, about 10% of our MMF patients had concurrent MS-
like disease (78), an additional 5–10% had another autoimmune
disease, such as thyroiditis and diffuse inflammatory myopathies,
and the remaining patients occasionally had low titers of various
autoantibodies (46).
Yehuda Shoenfeld had delineated the “autoimmune (autoin-
flammatory) syndrome induced by adjuvants” (ASIA)(79),
acknowledging that various combinations of (i) specific autoim-
mune diseases identified by well-established criteria, (ii) less-
specific symptoms, such as myalgia, arthralgia, chronic fatigue,
and cognitive impairment (the combination of which defines
ME/CFS); and (iii) the appearance of circulating autoantibod-
ies, can occur after exposure to a variety of chemical or natural
products with immunological adjuvant properties. Discussion of
the ASIA is very useful since it may alert physicians, when they
encounter the above-mentioned symptoms, to check for prior
vaccinations, and may help them to put a name on such conditions.
Symptoms associated with MMF are strikingly similar to those
described as the Gulf war syndrome (GWS), a condition strongly
associated with the administration of multiple vaccinations to sol-
diers (80, 81), especially the anthrax vaccine that contains alum,
capable of inducing MMF (82), and possibly squalene (83). On
these grounds, we proposed to delineate a vaccine adjuvant syn-
drome (84). Yehuda Shoenfeld reasoned similarly but added to
GWS and MMF, his own experience on siliconosis, a disease
complex observed in patients with leaky breast silicone implants
attributed to deleterious adjuvanticity of silicone particles (85, 86).
In so-doing, he enlarged the causal relationship to any compound
with adjuvant properties. ASIA major and minor diagnostic crite-
ria still need international validation but the ASIA concept already
caught the attention of the international human and veterinary
medical community, pointing out a need in the field (87, 88).
A LOT MUST BE DONE TO UNDERSTAND HOW, IN CERTAIN
INDIVIDUALS, ALUM-CONTAINING VACCINES MAY BECOME
INSIDIOUSLY UNSAFE
Alum has been used for decades to levels considered as an accept-
able compromise between its role of adjuvant and its toxic effects
by the industry and the regulatory agencies. However, the MMF
story revealed several gaps in the knowledge on alum particles,
including their exact mechanisms of action, their fate after injec-
tion, their systemic dissemination, and their safety on the long-
term. Efforts have been done in the last years to develop novel
adjuvants, but attempts to seriously examine safety concerns raised
by the bio-persistent character and brain accumulation of alum
particles have not been made.
The main questions that should be addressed concerning alum
safety problems are listed in Table 1. It is important to look
for genetic susceptibility factors that could explain why a given
individual will appear intolerant to alum-containing vaccines
whereas the vast majority of individuals vaccinated with the same
vaccines remain healthy. Some patients with MMF are of the
HLA-DRB1*01group, which is associated with an increased risk
to develop autoimmune diseases (89). Genetic factors influenc-
ing alum biodistribution were also investigated. In keeping with
experimental evidence that the CCL2/MCP-1 chemokine signal-
ing governs brain translocation of phagocytosed particles (5), and
that CCL2/MCP-1 serum levels are selectively increased in patients
with MMF (45), genotyping of 252 symptomatic MMF patients
and 516 healthy controls for 4 single nucleotide polymorphisms
(SNPs) localized in the CCL2 gene showed that the AG haplo-
type of the SNP rs3760396C( −927G>C) was associated with a
slightly increased risk for disease (5). Interestingly, the rs 3760396
C allele is associated with a higher level of expression of CCL2
in vitro as assessed by transfection (90). These preliminary results
deserve further investigations. Another axis of research consists in
attempts to detect if subtle genetically determined defects in the
Frontiers in Neurology | Neurodegeneration February 2015 | Volume 6 | Article 4 | 4
Gherardi et al. Biopersistence of alumic adjuvant
Table 1 | Main unsolved questions linked to alum adjuvants toxic
effects.
WHAT ISTHE MOSTTOXIC?
Al3+metal toxicity (or allergy to Al)
Particle toxicity due to elementary nanoparticles, e.g., mitochondrial
toxicity, or to the micronic agglomerates they form, e.g., proinflammatory
effects
Immune reactions against biopersistent biomolecules adsorbed on alum,
and protected from degradation until complete particle solubilization
(vaccine antigen or trace residual DNA sequences linked to vaccine
production, or even self-antigens adsorbed on alum at time of
injection-induced muscle necrosis)
WHAT FACTORS CONTRIBUTETO BIOPERSISTENCE?
The quantity administered
Adsorbed molecules impeding extracellular solubilization and/or favoring
phagocytosis of alum particles
Crystalline structure of the adjuvant damaging lipid bilayers (e.g.,
lysosomes)
WHAT FACTORS CONTRIBUTETO BRAINTRANSLOCATION?
Al3+ ion transport by transferrin (receptors present in CNS increase with
iron deficiency)
Direct BBB damage by alum particles (proportion and kinetics in the
circulation are unknown)
Monocyte cell transport of particles (the MCP1/CCL2-dependent Troian
horse mechanism is increased in case of altered BBB and/or
neuroinflammation)
WHATARETHE SUSCEPTIBILITY FACTORS?
Individual environment (other exposures to Al, exposure to other metals,
exposure to other particles, chronic viral infection)
Age of immunization, including early age (low body weight, immature BBB,
early neurodevelopmental stage) and old age (increased MCP-1/CCL2
production, progressive BBB weakness, hidden neuropathological
processes)
Genetic factors impacting either immunologic responses (e.g., HLA
genotypes) or intracellular persistence of particles (xeno/autophagy
genes), or neuromigration (chimiokines and other inflammation genes)
cell machinery used to clear out particles, namely autophagy (91),
could contribute to the long-standing biopersistence of alum par-
ticles, as previously reported to explain intracellular persistence
of intestinal pathogens in Crohn’s disease (92). Cells coping with
microbes use a dedicated form of autophagy termed “xenophagy”
as a host defense mechanism to engulf and degrade intracellu-
lar pathogens. The same holds true for inert particles subjected
to phagocytosis/endocytosis (93). As mentioned above, crystal
particles are likely toxic to membranes, which may destabilize
phagosomes and lysosomes, trigger inflammasome assembly, and
impede the autophagy pathways (32–35, 39). However, crystal par-
ticles instead of killing macrophages promote their survival (17).
Thus, macrophages will continuously perceive as foreign particles
in their cytosol, just like senescent organelles or bacteria, and will
likely reiterate the autophagic process until they dispose of alien
materials. The process includes compartmentalization of parti-
cles within double membrane autophagosomes and subsequent
fusion with repaired and re-acidified lysosomes, exposing antigen-
bound alum particles to lysosomal acidic pH, the sole factor that
can solubilize alum crystal and acid hydrolases that will degrade
the antigen. The process involves a conserved pathway in which
particles decorated by ubiquitinated proteins, recruit the adaptor
protein p62/SQSTM1 (sequestosome 1), which targets the whole
to the autophagosome through binding to the autophagosomal
membrane protein LC3/Atg8 (94, 95). Autophagosomes forma-
tion also involves other Atg molecules, such as the high molecular
weight complex (Atg12–Atg5–Atg16L), Atg7, and many others,
and is regulated by IRGM (immunity-related GTPase family-
M1). The autophagosome external membrane eventually fuses
with lysosomes. Genes of all molecules of the autophagy pathway
are subjected to variations that are currently screened in patients
with MMF.
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